Killer Cells, Lymphokine-Activated
"Killer Cells, Lymphokine-Activated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
| Descriptor ID |
D015979
|
| MeSH Number(s) |
A11.118.637.555.283.500 A11.118.637.555.567.537.500 A15.145.229.637.555.283.500 A15.145.229.637.555.567.537.500 A15.382.490.555.283.500 A15.382.490.555.567.537.500
|
| Concept/Terms |
Killer Cells, Lymphokine-Activated- Killer Cells, Lymphokine-Activated
- Cell, Lymphokine-Activated Killer
- Cells, Lymphokine-Activated Killer
- Killer Cell, Lymphokine-Activated
- Killer Cells, Lymphokine Activated
- Lymphokine-Activated Killer Cell
- Lymphokine-Activated Killer Cells
- Lymphokine Activated Killer Cells
- LAK Cells
- Cell, LAK
- Cells, LAK
- LAK Cell
|
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Lymphokine-Activated".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.283.500]
- Lymphocytes [A11.118.637.555.567]
- Killer Cells, Natural [A11.118.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.567.537.500]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.283.500]
- Lymphocytes [A15.145.229.637.555.567]
- Killer Cells, Natural [A15.145.229.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.145.229.637.555.567.537.500]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.283.500]
- Lymphocytes [A15.382.490.555.567]
- Killer Cells, Natural [A15.382.490.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.567.537.500]
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Lymphokine-Activated".
This graph shows the total number of publications written about "Killer Cells, Lymphokine-Activated" by people in this website by year, and whether "Killer Cells, Lymphokine-Activated" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 3 | 5 |
| 1995 | 1 | 1 | 2 |
| 1996 | 3 | 2 | 5 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Killer Cells, Lymphokine-Activated" by people in Profiles.
-
Cellular immunotherapy for high-grade glioma. Immunotherapy. 2011 Mar; 3(3):423-34.
-
Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol. 2010 Oct 15; 185(8):4793-803.
-
Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm. 2006 Oct; 21(5):515-9.
-
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother Radiopharm. 2006 Oct; 21(5):437-42.
-
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer. 2000 Jul 01; 87(1):101-9.
-
IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol. 2000 Jun 15; 164(12):6244-51.
-
Multiple interleukin-2 signaling pathways differentially regulated by microgravity. Immunopharmacology. 1999 Nov; 44(3):273-9.
-
Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys. AIDS Res Hum Retroviruses. 1998 Mar 20; 14(5):393-9.
-
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother. 1998 Feb; 45(6):287-98.
-
Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. J Interferon Cytokine Res. 1997 Aug; 17(8):435-47.